KLBF.JK

PT Kalbe Farma Tbk. [KLBF.JK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

KLBF.JK Stock Summary

Earnings have grown 10.18% per last year.

Earnings are expected to rise 29.06% next year

EPS has been increasing for the past 3 years (Yearly statements)

KLBF.JK's dividend payments are well covered by cash flows with cash payout ratio of 59.35%.

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.1%) are lower than the previous year (0.12%)

Top 10 Correlated ETFs

KLBF.JK

Top 10 Correlated Stocks

KLBF.JK

In the News

KLBF.JK Financial details

Company Rating

Buy

Market Cap

73777.68B

Income

2961.62B

Revenue

30312.74B

Book val./share

Cash/share

Dividend

Dividend %

2.37%

Employees

13.17K

Optionable

Shortable

Yes

Earnings

31 Oct 2023

P/E

25.21

Forward P/E

18.85

PEG

-10.83

P/S

2.45

P/B

3.61

P/C

P/FCF

34.72

Quick Ratio

2.17

Current Ratio

3.9

Debt / Equity

0.05

LT Debt / Equity

0.01

EPS (TTM)

52.11

EPS next Y

84.9

EPS next Q

EPS this Y

7.05%

EPS next Y

62.92%

EPS next 5Y

76.29%

EPS last 5Y

6.76%

Revenue last 5Y

6.54%

Revenue Q/Q

0.99%

EPS Q/Q

SMA20

-5.79%

SMA50

-9.51%

SMA100

-19.76%

Inst Own

Inst Trans

ROA

11%

ROE

14%

ROC

0.17%

Gross Margin

39%

Oper. Margin

13%

Profit Margin

10%

Payout

Shs Outstand

46.26B

Shs Float

18.96B

Target Price

52W Range

1550.0-2360.0

52W High

-32.2%

52W Low

+3.23%

RSI

41.05

Rel Volume

0.35

Avg Volume

29.55M

Volume

10.28M

Perf Week

-1.54%

Perf Month

-11.36%

Perf Quarter

-21.57%

Perf Half Y

-24.17%

Beta

0.251

Volatility

18.65%, 72.05%

Prev Close

-0.31%

Price

1600

Change

-1.54%

KLBF.JK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	449.58	482.85	493.07	560.26	622.01
Net income per share	52.42	53.48	58.31	67.92	72.71
Operating cash flow per share	59.11	53.4	89.92	60.29	81.04
Free cash flow per share	29.82	11.09	66.06	38.94	62.33
Cash per share	71.08	69.04	115.12	138.14	88.04
Book value per share	311.97	339.05	371.32	417.71	438.24
Tangible book value per share	316.38	341.61	375.09	428.99	442.2
Share holders equity per share	311.97	339.05	371.32	417.71	438.24
Interest debt per share	8.04	18.09	26.32	14.33	25.99
Market cap	71250.19B	75937.7B	69374.46B	75699.81B	97218.32B
Enterprise value	68454.27B	73714.06B	65324.34B	70109.72B	94436.26B
P/E ratio	29	30.29	25.38	23.78	28.74
Price to sales ratio	3.38	3.36	3	2.88	3.36
POCF ratio	25.71	30.34	16.46	26.79	25.79
PFCF ratio	50.98	146.02	22.4	41.48	33.53
P/B Ratio	4.87	4.78	3.99	3.87	4.77
PTB ratio	4.87	4.78	3.99	3.87	4.77
EV to sales	3.25	3.26	2.83	2.67	3.26
Enterprise value over EBITDA	18.41	19.99	16.43	15.55	19.35
EV to operating cash flow	24.71	29.45	15.5	24.81	25.05
EV to free cash flow	48.97	141.75	21.1	38.41	32.57
Earnings yield	0.03	0.03	0.04	0.04	0.03
Free cash flow yield	0.02	0.01	0.04	0.02	0.03
Debt to equity	0.02	0.05	0.07	0.03	0.06
Debt to assets	0.02	0.04	0.05	0.02	0.04
Net debt to EBITDA	-0.75	-0.6	-1.02	-1.24	-0.57
Current ratio	4.66	4.35	4.12	4.45	3.77
Interest coverage	167.49	110.04	47.96	91.47	108.97
Income quality	1.13	0	0	0	1.11
Dividend Yield	0.02	0.02	0.02	0.02	0.02
Payout ratio	0.48	0.49	0.45	0.41	0.48
Sales general and administrative to revenue	0.02	0.02	0.02	0.02	0.02
Research and developement to revenue	0.02	0.02	0.02	0.02	0.01
Intangibles to total assets	0.03	0.03	0.03	0.05	0.06
Capex to operating cash flow	-0.5	-0.79	-0.27	-0.35	-0.23
Capex to revenue	-0.07	-0.09	-0.05	-0.04	-0.03
Capex to depreciation	0	0	0	0	-2.25
Stock based compensation to revenue	0	0	0	0	0
Graham number	606.58	638.72	697.97	798.97	846.73
ROIC	0.17	0.15	0.15	0.16	0.16
Return on tangible assets	0.14	0.13	0.12	0.13	0.13
Graham Net	107.99	100.07	126.53	164.19	141.98
Working capital	8362.12B	8645.38B	9898.61B	12177.55B	12279.19B
Tangible asset value	14830.29B	16013.13B	17582.23B	20108.07B	20569.21B
Net current asset value	7796.68B	7663.35B	8787.11B	11311.45B	11566.24B
Invested capital	0.02	0.05	0.07	0.03	0.06
Average receivables	3623.27B	3992.93B	4112.01B	4067.41B	4811.75B
Average payables	1199.22B	1252.88B	1228.12B	1453.99B	1832.11B
Average inventory	3516.04B	3606.28B	3668.86B	4343.52B	6057.33B
Days sales outstanding	65.69	67.62	63.65	57.04	69.63
Days payables outstanding	41.94	35.82	35.19	40.64	42.3
Days of inventory on hand	112.97	110.12	102.12	123.98	148.87
Receivables turnover	5.56	5.4	5.73	6.4	5.24
Payables turnover	8.7	10.19	10.37	8.98	8.63
Inventory turnover	3.23	3.31	3.57	2.94	2.45
ROE	0.17	0.16	0.16	0.16	0.17
Capex per share	-29.29	-42.3	-23.86	-21.35	-18.71

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	313.59K	166.65	169.17	157.15	0
Net income per share	36.42K	19.28	18.4	14.47	0
Operating cash flow per share	40.29K	21.9	18.4	7.23	0
Free cash flow per share	28.77K	16.51	14.26	1.08	0
Cash per share	185.05K	88.04	77.96	62.13	0
Book value per share	835.58K	438.24	455.77	432.31	0
Tangible book value per share	855.83K	442.2	459.79	432.5	0
Share holders equity per share	835.58K	438.24	455.77	432.31	0
Interest debt per share	46.92K	25.41	19.49	40.24	0
Market cap	42.64B	97218.32B	97683.48B	95357.68B	0
Enterprise value	3016.31B	94436.26B	95091.09B	94461.03B	1732.28B
P/E ratio	0.01	27.1	28.54	35.41	0
Price to sales ratio	0.01	12.54	12.41	13.05	0
POCF ratio	0.05	95.43	114.15	283.73	0
PFCF ratio	0.06	126.57	147.32	1.9K	0
P/B Ratio	0	4.77	4.61	4.74	0
PTB ratio	0	4.77	4.61	4.74	0
EV to sales	-0.41	12.18	12.08	12.92	-0.23
Enterprise value over EBITDA	-2.52	69.07	76.53	105.89	-2.12
EV to operating cash flow	-3.21	92.7	111.12	281.06	-1.84
EV to free cash flow	-4.5	122.95	143.41	1.88K	-2.64
Earnings yield	19.9	0.01	0.01	0.01	0
Free cash flow yield	15.72	0.01	0.01	0	0
Debt to equity	0.06	0.06	0.04	0.09	0.05
Debt to assets	0.04	0.04	0.03	0.07	0.04
Net debt to EBITDA	-2.56	-2.03	-2.09	-1.01	-2.12
Current ratio	3.8	3.77	3.81	3.35	3.9
Interest coverage	132.28	86.05	63.33	31.75	31.02
Income quality	1.11	1.14	1	0	0
Dividend Yield	1.81	0	0	0	0
Payout ratio	0.09	0	0	0	0
Sales general and administrative to revenue	0.01	0.02	0.01	0.02	0.01
Research and developement to revenue	0.02	-0.01	0.01	0.03	0.02
Intangibles to total assets	0.05	0.06	0.05	0.06	0.06
Capex to operating cash flow	-0.29	-0.25	-0.23	-0.85	-0.3
Capex to revenue	-0.04	-0.03	-0.02	-0.04	-0.04
Capex to depreciation	-2.98	-2.05	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	827.43K	435.98	434.34	375.22	0
ROIC	0.04	0.04	0.04	0.03	0.03
Return on tangible assets	0.03	0.03	0.03	0.03	0.02
Graham Net	276.61K	141.98	146.53	122.21	0
Working capital	11896.17B	12279.19B	12956.48B	11679.2B	12137.74B
Tangible asset value	19942.46B	20569.21B	21387.38B	20118.31B	20692.85B
Net current asset value	11111.1B	11566.24B	12249.53B	11015.9B	11508.35B
Invested capital	0.06	0.06	0.04	0.09	0.05
Average receivables	5002.9B	5327.17B	5886.22B	6282.25B	6198.1B
Average payables	1935.42B	1981.89B	2228.59B	2272.16B	1992.24B
Average inventory	6332.61B	6834.28B	7331.81B	7522.03B	7298.95B
Days sales outstanding	63.24	64.08	71.52	77.71	74.18
Days payables outstanding	40.51	37.58	47.62	43.08	36.78
Days of inventory on hand	136.75	132.25	147.8	153.14	139.14
Receivables turnover	1.42	1.4	1.26	1.16	1.21
Payables turnover	2.22	2.4	1.89	2.09	2.45
Inventory turnover	0.66	0.68	0.61	0.59	0.65
ROE	0.04	0.04	0.04	0.03	0.03
Capex per share	-11.52K	-5.39	-4.14	-6.15	0

KLBF.JK Dividend History

KLBF.JK Frequently Asked Questions

What is PT Kalbe Farma Tbk. stock symbol ?

PT Kalbe Farma Tbk. is a ID stock and trading under the symbol KLBF.JK

What is PT Kalbe Farma Tbk. stock quote today ?

PT Kalbe Farma Tbk. stock price is $1600 today.

Is PT Kalbe Farma Tbk. stock public?

Yes, PT Kalbe Farma Tbk. is a publicly traded company.

Something similar

Top by Market Cap

GOOGL

LLY.DE

Company Profile

Volume Average 29.55M
Market Capitalization 73777.68B
Employee 13.17K
CEO Mr. - Vidjongtius
Headquarters Jakarta,ID
IPO Date 2003-12-15
Website https://www.kalbe.co.id

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.